Bortezomib (VELCADE), Rituximab, Cyclophosphamide, Dexamethasone (VRCD) combination therapy
Bortezomib (VELCADE), Rituximab, Cyclophosphamide, Dexamethasone (VRCD) combination therapy in front-line low-grade non-Hodgkin lymphoma (LG-NHL) is active in elderly patient population. Chadi Nabhan MD FACP, Neil Dalal DO, Kathy Tolzien RN, Alexander Starr MD
981 views • 1 slides